Related Experiment Video

Updated: Jul 2, 2025

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

19.5K

Inside anticancer therapy resistance and metastasis. Focus on CD36

Ioana M Lambrescu1,2, Gisela F Gaina1,2, Laura C Ceafalan1,2

  • 1Cell Biology, Neurosciences, and Experimental Myology Laboratory, Victor Babeș Institute of Pathology, 050096 Bucharest, Romania.

Journal of Cancer
|February 19, 2024
PubMed

Insights

CD36, a lipid receptor, is implicated in cancer drug resistance. Targeting CD36 offers new strategies for overcoming treatment resistance in various cancers, paving the way for personalized medicine.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Drug resistance is a major challenge in cancer therapy.
  • Lipid metabolism plays a crucial role in cancer progression and metastasis.
  • CD36, a lipid transporter, is linked to poor prognosis in various cancers.

Purpose of the Study:

  • To review the role of CD36 in resistance to cancer therapies.
  • To explore CD36's involvement in both solid and hematological malignancies.
  • To summarize emerging anti-CD36 therapies for personalized medicine.

Main Methods:

  • Literature review of studies on CD36 and cancer drug resistance.
  • Analysis of CD36's role in resistance to platinum-based and adjuvant therapies.
  • Overview of current and developing anti-CD36 therapeutic strategies.

Main Results:

  • CD36 expression is associated with resistance to various cancer treatments.
  • CD36 contributes to drug resistance in both solid tumors and hematological cancers.
  • Emerging therapies targeting CD36 show promise for overcoming treatment resistance.

Conclusions:

  • CD36 is a critical factor in cancer treatment resistance.
  • Targeting CD36 presents a promising avenue for novel cancer therapies.
  • Further research into anti-CD36 strategies could lead to personalized cancer medicine.
Keywords:
CD36cancer treatmentchemotherapydrug resistancelipid metabolism

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells12:14

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

2.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K